Long-term research is limited on Tirzepatide, whereas there is more available research on Semaglutide
Studies have also revealed a relationship between poor sleep quality and HPA activation, which usually results in cortisol production
This is supported by the fact that abnormal IGF-1 levels are associated with insulin resistance [40], which worsens stroke outcome [41]
P., Siebel, S., Akingbesote, N
It is important to note that oral semaglutide is not currently FDA-approved for weight management as a primary indication, whereas injectable semaglutide has specific approval for chronic weight management at the 2.4 mg dose
The data reveals patterns so consistent they appear in roughly 85% of patients who complete treatment